3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Neoplasms
5
Healthy Participants
5
Breast Neoplasms
5
Prostatic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Venous Thromboembolism
2
Solid Tumor, Adult
2
Neoplasm Metastasis
2
Healthy Volunteers
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Cardiovascular Diseases
2
cMET-dysregulated Advanced Solid Tumors
1
Venous Thrombosis
1
TP53 Y220C Mutation
1
Stroke
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Rectal Neoplasms
1
Pulmonary Embolism
1
Prostatic Neoplasms, Castration-Resistant
1
Precancerous Conditions
1
Peripheral Nervous System Diseases
1
Pain
1
Ovarian Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Melanoma
1
Liver Cirrhosis
1
Leiomyosarcoma
1
Interventions
Doxorubicin
17
Cyclophosphamide
16
Ifosfamide
11
fludarabine
9
Radiotherapy
8
tazemetostat
4
pembrolizumab
4
pazopanib
4
Gemcitabine
4
pegfilgrastim
3
cixutumumab
3
Trabectedin
3
Radiation
3
Imatinib Mesylate
3
Filgrastim
3
Docetaxel
3
Dacarbazine
3
sargramostim
2
liposomal doxorubicin
2
fludarabine phosphate
2
brostallicin
2
aldesleukin
2
X-Rays
2
Sunitinib
2
Specimen Handling
2
Sorafenib
2
Radiation Dose Hypofractionation
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Leukapheresis
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Sarcoma, Synovial
×
Rosuvastatin Calcium
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled